Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117598 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT00117598 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 169 participants.
The verdict
NCT00117598, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
Interventions
- DRUG Investigator's choice
- DRUG Temsirolimus (CCI-779)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117598
The ClinicalTrials.gov registry entry for NCT00117598 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Investigator's choice is the first listed.
NCT00117598 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117598 about?
NCT00117598 is a clinical study titled "Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)". This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).
What is the current status of trial NCT00117598?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2005-05. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00117598?
The interventions under investigation include: Investigator's choice (DRUG), Temsirolimus (CCI-779) (DRUG).
Who is sponsoring clinical trial NCT00117598?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.